Dr. Xin Gao from Harvard Medical School shares new insights on sacituzumab govitecan's efficacy in metastatic urothelial cancer patients and examines future research prospects.
Adjuvant therapy with the immune checkpoint inhibitor nivolumab following surgery improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma, according to new findi...
Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according t...
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate...
Several years ago, Samuel Denmeade, M.D., Director of the Division of Genitourinary Oncology at the Sidney Kimmel Comprehensive Cancer Center, and colleagues came up with a new concept for treating advanced prostate cancer that seemed counterintuitive: they gave a patient testosterone, lots of it. And then they took it away with androgen deprivation therapy (ADT). And then they gave high-dose testosterone again. And then more ADT.
Johns Hopkins Medicine
Daily News
Stay up to date with the latest clinical headlines.
In previously treated patients with advanced or metastatic clear cell renal cell carcinoma, a subcutaneous formulation of nivolumab was noninferior to the intravenous formulation, according to results...
Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study...
The latest advances in surgical cancer care and research were showcased at the Society of Surgical Oncology’s (SSO) Annual Meeting, the International Conference on Surgical Cancer Care. The meeting was held in Boston, from March 22 – 25, 2023.